GHRH(1-29)NH2 Stimulates Growth and Secretion in Human Lung Neuroendocrine Tumor Cells
Background
Growth hormone-releasing hormone (GHRH) and its receptors are known to influence various cellular processes, including cell proliferation, angiogenesis (the formation of new blood vessels), and neoplastic transformation (the process of normal cells becoming cancerous) in non-pituitary tissues. However, the specific impact of GHRH on human bronchial neuroendocrine tumor (NET) cells has been largely unexplored. This study investigated for the first time the in vitro effects of GHRH(1-29)NH2 on the proliferation and secretion of key markers in human bronchial neuroendocrine tumor cells.
Results
The study found that GHRH(1-29)NH2 significantly stimulated the proliferation of NCI-H727 cells across all tested concentrations, indicating a consistent trophic (growth-promoting) response. This proliferative effect was robust, showing a clear increase compared to untreated control cells. > Importantly, this increased proliferation was associated with a statistically significant increase in both VEGF and chromogranin A secretion into the cell culture supernatants. Specifically, cells treated with GHRH(1-29)NH2 showed elevated levels of these markers, suggesting enhanced tumor growth and angiogenic potential. While specific fold-changes or exact p-values were not detailed in the abstract, the increases were consistently reported as statistically significant.
Why It Matters
These findings are significant as they identify GHRH as a trophic hormone for bronchial neuroendocrine tumors, meaning it actively promotes their growth and activity. This discovery suggests that GHRH receptors could represent novel therapeutic targets for managing or treating bronchial NETs. If GHRH signaling can be inhibited, it might offer a new strategy to slow tumor progression or reduce angiogenesis in patients with these challenging cancers. Future research should focus on validating these in vitro results with in vivo animal models and eventually exploring GHRH receptor antagonists as potential drug candidates for clinical trials.